Small extracellular vesicles (sEVs), commonly referred to as exosomes, are nanoscale vesicles that mediate intercellular communication and represent promising biotechnological platforms for disease diagnosis, therapeutic intervention, and drug delivery. sEVs derived from plants, mesenchymal stem cells, tumor cells, and immune cells display pronounced source-dependent heterogeneity shaped by parental cell lineage, differentiation status, and the local microenvironment. Such heterogeneity influences not only their biological properties, including physicochemical characteristics, molecular cargo profiles, and immunomodulatory functions, but also their manufacturing characteristics, in vivo tropism, and translational potential as biotherapeutics. Nevertheless, a comprehensive evaluation framework from a medical biotechnology perspective remains insufficiently established. In this review, the core biological features of multi-source sEVs are first outlined to establish a foundation for subsequent analysis. We then examine their biomedical applications and discuss biotechnological bottlenecks, including isolation and purification workflows, quality-control metrics, batch-to-batch variability, scalable biomanufacturing, and biosafety assessment. Particular attention is also given to the incompletely characterized regulatory networks of immune-cell-derived sEVs. Furthermore, we discuss how multi-omics profiling, standardized production protocols, and precision-engineering strategies may facilitate the functional optimization of source-specific sEVs. Collectively, this review provides an integrated medical biotechnology framework for evaluating multi-source sEVs and highlights practical considerations for accelerating the bench-to-bedside translation of sEV-based biotherapeutics.